Search clinical trials for: STN1010904 ophthalmic suspension 0.1% BID

Total 673 results

Santen Inc.
ActualEyes Inc.

Active, not recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States, France, India
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Inflammation and Pain Following Ocular Surgery

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Ocular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract Surgery

United States
Alcon Research

Withdrawn

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

Bacterial Conjunctivitis
Aldeyra Therapeutics, Inc.

Completed

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Dry Eye

United States
Hanlim Pharm. Co., Ltd.

Completed

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

Healthy Subject
Bausch & Lomb Incorporated

Completed

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

Dry Eye Syndrome

United States
Alcon Research

Completed

Confirmatory Study Nepafenac 0.3%

Cataract

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

Post Surgical Ocular Inflammation and Pain

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Dry Eye

United States
Alcon Research

Completed

Nepafenac 0.3% Two Study

Cataract

United States
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
IVIEW Therapeutics Inc.

Not yet recruiting

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye Disease

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Dry Eye Syndromes

United States
Laboratorios Sophia S.A de C.V.

Completed

Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease. (PRO-037)

Dry Eye

Mexico
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Corneal Scar

United States
Cornea Consultants Of Nashville
Bausch & Lomb Incorporated; SCRI Development Innovations, LLC

Terminated

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. (Eye02)

Corneal Ulcers

United States
Toyos Clinic
Bausch & Lomb Incorporated

Completed

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Inflammation | Pseudophakia
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (OPSIS)

Presbyopia

United States
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

Neurotrophic Keratitis

United States, Canada
Santen Inc.

Completed

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Dry Eye

United States
Betaliq, Inc.
Trial Runners, LLC; Summit Analytical, LLC

Completed

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
TetraLogic Pharmaceuticals
PPD; The Leukemia and Lymphoma Society; Veristat, Inc.; Therapeutics, Inc.

Completed

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

Lymphoma, T-Cell, Cutaneous

United States
Aldeyra Therapeutics, Inc.
ORA, Inc.

Completed

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Conjunctivitis, Allergic

United States
Allysta Pharmaceutical

Completed

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Azura Ophthalmics
ORA, Inc.

Not yet recruiting

A Phase 3 Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Dry Eye Disease

United States
Aldeyra Therapeutics, Inc.

Completed

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis | Seasonal Allergies

Canada
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With DED (STRIDE 3)

Kerato Conjunctivitis Sicca

United States
Hanlim Pharm. Co., Ltd.

Completed

A Dose-escalation Clinical Trial After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects

Healthy Subjects

France
Allergan

Completed

A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin

Ocular Hypertension

United States
Incyte Corporation

Completed

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States
Bausch & Lomb Incorporated

Completed

LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Pain | Ocular Inflammation | Cataract

United States
Rigel Pharmaceuticals

Completed

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca (DROPS)

Keratoconjunctivitis Sicca

United States
University of Trieste

Completed

PGE2 Levels in Patient Treated With NSAIDs

Ocular Inflammation

Italy
Rigel Pharmaceuticals

Completed

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Alcon Research

Completed

Adjunctive Study of AL-37807 Ophthalmic Suspension

Ocular Hypertension | Open-Angle Glaucoma

United States
Biomedisyn Corporation
Yale University

Completed

Huperzine for Cognitive and Functional Impairment in Schizophrenia

Schizophrenia

United States
Alcon Research

Completed

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma
Topivert Pharma Ltd

Completed

Study of TOP1630 for Dry Eye Syndrome (THEIA-1)

Dry Eye Syndrome

United States
Johns Hopkins University

Completed

Study of Ocular Penetration of Topically Administered Fluoroquinolones

Cataract Extraction

United States
Alcon Research

Terminated

Macular Edema Incidence/Severity Reduction With Nevanac

Diabetic Retinopathy

United States
Alcon Research

Completed

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Terminated

Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination

Ocular Hypertension | Open-Angle Glaucoma
ParaPRO LLC
Concentrics Research

Completed

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

Scabies

United States

3

Subscribe